Loading clinical trials...
Loading clinical trials...
Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial
Conditions
Interventions
medium dosage inactivated SARS-CoV-2 vaccine
high dosage inactivated SARS-CoV-2 vaccine
+1 more
Locations
1
China
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, China
Start Date
October 7, 2020
Primary Completion Date
June 30, 2021
Completion Date
February 28, 2022
Last Updated
February 17, 2021
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Beijing Minhai Biotechnology Co., Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions